ABOS Share Price Performance
US$2.35
1.31 (125.96%)
76.5% undervalued intrinsic discount
US$10.00
Fair Value
Price US$2.35
AnalystHighTarget US$10.00
Fair ValueUS$10.00
Share Pricen/a
New Narrative • May 17
Acumen Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
ABOS Community Narratives
AN
Fair Value
·Fair Value US$10 76.5% undervalued intrinsic discount
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Acumen Pharmaceuticals is betting that a more precise kind of Alzheimer’s antibody—and new ways to get drugs deeper into the brain—can deliver better results than today’s treatments. The next big readout from its ongoing study could validate that approach, but a miss or slow doctor and insurer adoption could leave the company stuck burning cash.Read more
AN
US$10
76.5% undervalued intrinsic discount
Fair Value
Profit Margin
18.87%
Future PE
419.88x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Oligomer Antibody And Brain Delivery Advances Will Reshape Early Alzheimer Treatment Prospects
Fair Value: US$10 76.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Acumen Pharmaceuticals, Inc. Key Details
About ABOS
- Founded
- 1996
- Employees
- 61
- CEO
- WebsiteView website
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
